Pauling

What Pauling does

Pauling.AI is a Boston-based, venture-backed company founded in 2024 that has developed Autochem, a conversational AI-driven autonomous drug discovery platform. The platform orchestrates 15+ computational chemistry pipelines including GPU-accelerated molecular docking (Uni-Dock, derived from AutoDock Vina), all-atom molecular dynamics simulations (GROMACS with AMBER99SB-ILDN force field), MM-PBSA binding free energy analysis, P2Rank binding pocket prediction, MolProbity and PoseBusters quality control, and ADMET property prediction across 80+ endpoints. The system integrates state-of-the-art third-party AI models (Boltz, DiffDock, AlphaFold 2/3) with physics-based methods via multi-LLM AI agents, running on Google Cloud Dataflow with auto-scaling infrastructure. Target users are medicinal chemists and research scientists who can describe a protein target in plain language and receive validated drug candidates without computational chemistry expertise.

The company serves biopharmaceutical companies, academic research labs, longevity-focused biotechs, and medicinal chemistry personnel, with pain points centered on 10–15 year drug discovery timelines, $2.6B per-approval costs, and 90% industry failure rates. Revenue is generated primarily through a $10,000 standard hit screening package covering 10 million compound docking plus MD validation for the top 100 candidates with approximately one-week turnaround, supplemented by custom enterprise pricing for pharmaceutical leaders and tailored multi-year contracts for academic and ongoing research collaborations. The go-to-market combines enterprise field sales (demo requests via [email protected]) with a product-led growth motion through the self-serve web interface at autochem.pauling.ai, supported by content marketing (Substack blog, The Pauling Principle podcast) and earned media coverage in tech and longevity publications.

Name

Pauling

Legal name

Pauling.AI

Website

https://pauling.ai

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Pauling.AI is a Boston-based company offering Autochem, an autonomous AI drug discovery platform that orchestrates molecular docking, dynamics, and ADMET prediction through a conversational interface for biopharma, academic, and longevity biotech customers lacking computational chemistry expertise.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Autonomous drug discovery
• AI drug discovery
• Computational chemistry platform
• Virtual screening software
• Molecular dynamics simulation

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Project-Based Drug Discovery Services: Standard hit screening package priced at $10,000 covering 10M compound docking plus MD validation for top 100 candidates. Turnaround time is approximately 1 week. Custom pricing available for ongoing research collaborations, academic institutions, and multi-target projects.
2. Enterprise Platform Access: Enterprise customers can access the platform for autonomous drug discovery. Pricing likely varies based on scope and usage, with tailored solutions for pharmaceutical leaders.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Pauling.AI operates the Autochem platform, a fully autonomous drug discovery system that lets users describe a protein target (e.g., '6VC8') in plain language and then automatically orchestrates molecular docking, molecular dynamics (GROMACS), ADMET prediction, and quality control to deliver validated drug candidates in days. The platform sells both standardized hit screening services (e.g., 10M-compound docking + MD validation for $10,000) and enterprise-grade platform access tailored to pharmaceutical, biotech, academic, and longevity research customers.

Product overview

Pauling.AI is a fully autonomous computational drug discovery platform that combines AI agents, enterprise-scale cloud infrastructure, and the latest AI models (Boltz, DiffDock) with physics-based computational chemistry methods. The core product is Autochem, which enables researchers to describe their target in plain language and receive validated drug candidates in days rather than years. Key offerings include: Hit Screening (docking up to 10 million compounds with MD validation); Docking Protocol (GPU-accelerated virtual screening with automated structure preparation and pocket prediction); Counterscreening Protocol (selectivity-focused dual-site docking); and MD/MM-PBSA ΔG Protocol (all-atom molecular dynamics with rigorous binding free energy calculations). The platform integrates with major compound libraries (Enamine, mCule) and protein structure databases (PDB, AlphaFold, UniProt) to deliver end-to-end automation of computational chemistry workflows.

Differentiator

Problem solved

Functional benefit

Brands

• Autochem: The computational drug discovery platform developed by Pauling.AI that automates molecular docking, molecular dynamics, and ADMET property prediction through AI agents.

Products and services

• Autochem The primary fully autonomous computational drug discovery platform that enables researchers to go from protein target to validated drug candidates in days through a conversational AI interface. It orchestrates molecular docking, molecular dynamics, ADMET prediction, and binding affinity analysis without requiring computational chemistry expertise, and is sold to pharmaceutical, biotech, and academic customers.
• Hit Screening Large-scale virtual screening service that docks up to 10 million compounds and applies MD validation for the top candidates. Delivers high-confidence hits with ADMET profiling and MM-PBSA free energy analysis in approximately 1 week for $10,000, targeting pharmaceutical and biotech researchers.
• Docking Protocol Virtual screening by molecular docking protocol using GPU-accelerated Uni-Dock. Includes automated structure acquisition, receptor preparation, P2Rank pocket prediction, two-stage docking, and PoseBusters quality control, designed for medicinal chemists conducting early-stage hit identification.
• Counterscreening Protocol Selectivity-focused virtual screening workflow that docks compounds against two binding sites simultaneously and ranks candidates by a selectivity score to identify selective binders over anti-targets. Used by medicinal chemists who need to profile off-target activity.
• MD / MM-PBSA ΔG Protocol Molecular dynamics hit validation protocol using all-atom MD simulations in explicit solvent followed by MM-PBSA binding free energy analysis. Includes GROMACS-based MD, AMBER99SB-ILDN force field, TIP3P water model, and per-residue energy decomposition for hit confirmation.
• Enterprise Enterprise tier offering for pharmaceutical companies featuring AI-native molecular discovery, physics-grounded explainable predictions, and scalable cloud infrastructure for accelerating R&D pipelines, with custom pricing and tailored solutions.

Quantifiable outcome

• 85% timeline reduction from initial hit identification to validated lead series
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration35 records

AI capability8 records

Feature8 records

Partnerships

Three partnerships are on record, tiered core.

• EnaminecoreTechnology or IntegrationEnamine is a major supplier of in-stock screening compounds. Pauling.AI's default screening libraries include approximately 10 million in-stock compounds from Enamine, prioritized because in-stock compounds eliminate procurement delays and allow immediate experimental validation.
• mCulecoreTechnology or IntegrationCompound supplier providing in-stock screening libraries. Part of Pauling.AI's ~10 million in-stock compound library for virtual screening.
• Google CloudcoreTechnology or IntegrationCloud infrastructure provider powering Pauling.AI's platform. Runs on Google Cloud Dataflow with enterprise-grade security and IP protection for processing millions of compounds in parallel.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• XtalPi: AI and quantum physics-based drug discovery platform combining computation with automated robotic wet-lab synthesis. Closely comparable to Pauling.AI's in-silico-to-validation pipeline, with a stronger wet-lab component and broader pharma partnerships.
• Atomwise: AI drug discovery platform using atom-level convolutional neural networks for structure-based small molecule design. Closely comparable technology stack and customer base (pharma/biotech hit discovery), directly serving the same virtual screening use case Pauling.AI targets.
• Iambic Therapeutics: AI-native drug discovery company using physics-informed machine learning for structure-based design and small molecule discovery. Comparable technology approach (combining physics-based and AI methods) and shared customer base in pharma/biotech.
• Exscientia: AI-driven precision medicine and drug discovery company using active learning and patient-derived data for molecule design. Comparable end-to-end AI drug discovery competitor with established pharma partnerships and an existing platform around automated compound design.
• Schrödinger: Public computational chemistry platform offering physics-based molecular simulation and drug design software. Directly comparable as the established 'complex tools' competitor named explicitly on Pauling.AI's comparison page, serving the same pharma/biotech customers with overlapping workflow tooling.
• BenevolentAI: AI drug discovery company applying machine learning to biomedical knowledge graphs and target identification. Comparable as another end-to-end AI pharma company pursuing the same thesis of compressing the early drug discovery funnel through automation.
• Insilico Medicine: AI-driven drug discovery company combining generative chemistry, target discovery, and clinical development. Comparable as one of the most well-funded end-to-end AI drug discovery competitors pursuing the same 'compressed timelines' thesis with much larger capital and longer operating history.
• Recursion Pharmaceuticals: AI-native drug discovery company combining high-throughput biology with machine learning across a broader phenotypic and target-based discovery footprint. Comparable as a competing AI drug discovery platform with significantly more capital and pipeline depth.

Broad incumbents

• Isomorphic Labs: Alphabet/DeepMind-backed drug discovery company leveraging AlphaFold and related foundation models. Comparable as a well-capitalized AI drug discovery competitor that Pauling.AI's stack explicitly integrates (AlphaFold, Boltz/DiffDock are included as workflow components).

Emerging players

• Crēdo Science: Emerging AI-native drug discovery platforms building workflow automation around generative biology and chemistry models — comparable as a similarly-staged early entrant in the same 'AI workflow for scientists' category as Pauling.AI.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pauling-ai
• Xx.com/PaulingAi

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pauling